Unresectable Hepatocellular carcinoma with Amit Singal, MD and Richard Finn, MD
CASE 2 : Unresectable Hepatocellular carcinoma (uHCC)
Richard G is a 64-year-old Caucasian night club owner from New Orleans, Louisiana with a history of alcohol and substance abuse, and alcohol-induced cirrhosis.
In April of 2012 the patient was diagnosed with unresectable hepatocellular carcinoma (uHCC), with a 4.6 x 4.3 cm mass detected in segment 6 of cirrhotic liver and evidence of macroscopic vascular invasion and extrahepatic spread to regional lymph nodes
TACE was recommended by the multidisciplinary team and the patient underwent a total of 2 TACE procedures, with a partial response observed (30% decrease in sum of greatest unidimensional diameters of target lesions compared to baseline) by RECIST criteria
In July 2013, follow up laboratory values were:
Albumin: 3.9 g/dL;
Bilirubin: 0.7 mg/dL
Alpha fetoprotein: 53.2 ng/mL
Platelets: 179,000
AST: 370 IU/mL
ALT: 189 IU/mL
The patient is classified as Child Pugh Class A at the current visit, with, with a MELD score of 10, and the patients ECOG performance status is 1
Contrast-enhanced MRI showed disease progression, with increases observed in diameter of multiple target lesions
FDA Supports Phase 3 Plan for Amezalpat in Hepatocellular Carcinoma
August 16th 2024The FDA has given positive feedback on the planned phase 3 study for the combination of amezalpat, atezolizumab, and bevacizumab in the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Read More
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
June 2nd 2024With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Read More